# Tirzepatide (Mounjaro)

*Also known as: Mounjaro, Tirz, Zepbound*

Dual GIP/GLP-1 agonist for weight loss and diabetes; weekly injection, strong efficacy.

## Overview

Tirzepatide (Mounjaro, Zepbound) is the first approved dual GIP and GLP-1 receptor agonist, developed for type 2 diabetes and chronic weight management. It mimics two incretin hormones: GLP-1 (which slows gastric emptying, suppresses appetite, and stimulates insulin) and GIP (which improves insulin sensitivity and reduces nausea). The dual mechanism produces greater weight loss than single GLP-1 agonists, with trial results reaching 22.5% body-weight reduction at the maximum dose. Its roughly 5-day half-life enables once-weekly subcutaneous dosing, with steady state reached after about 4 weeks. The standard titration escalates every 4 weeks from 2.5 mg to 15 mg to manage gastrointestinal side effects. Common effects include appetite suppression, delayed gastric emptying, and dose-dependent nausea. The compound is FDA-approved with an extensive clinical evidence base including cardiovascular outcomes trials.

## Pharmacokinetics

- **Model tier:** advanced
- **Half-life:** 4.9 days (116.69999999999999 hours)
- **Cmax:** 5826.67 nmol/L
- **Tmax:** 1.5 days
- **Bioavailability:** 80%

## Dosing

- **Default dose:** 5 mg
- **Typical range:** 2.5–15 mg
- **Units:** nmol/L

## Source

- **Label:** PMC tirzepatide PK
- **URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/

**Tags:** weight-loss, metabolic

---

**Canonical URL:** https://anabolicdex.com/compounds/tirzepatide
**Plot:** https://anabolicdex.com/plot?compound=tirzepatide